IL277144B2 - Adenosine receptor antagonists and uses thereof - Google Patents

Adenosine receptor antagonists and uses thereof

Info

Publication number
IL277144B2
IL277144B2 IL277144A IL27714420A IL277144B2 IL 277144 B2 IL277144 B2 IL 277144B2 IL 277144 A IL277144 A IL 277144A IL 27714420 A IL27714420 A IL 27714420A IL 277144 B2 IL277144 B2 IL 277144B2
Authority
IL
Israel
Prior art keywords
substituted
unsubstituted
compound
alkyl
pharmaceutically acceptable
Prior art date
Application number
IL277144A
Other languages
English (en)
Hebrew (he)
Other versions
IL277144B1 (en
IL277144A (en
Original Assignee
Teon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teon Therapeutics Inc filed Critical Teon Therapeutics Inc
Publication of IL277144A publication Critical patent/IL277144A/en
Publication of IL277144B1 publication Critical patent/IL277144B1/en
Publication of IL277144B2 publication Critical patent/IL277144B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
IL277144A 2018-03-05 2019-03-05 Adenosine receptor antagonists and uses thereof IL277144B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862638737P 2018-03-05 2018-03-05
US201862688088P 2018-06-21 2018-06-21
PCT/US2019/020810 WO2019173380A1 (en) 2018-03-05 2019-03-05 Adenosine receptor antagonists and uses thereof

Publications (3)

Publication Number Publication Date
IL277144A IL277144A (en) 2020-10-29
IL277144B1 IL277144B1 (en) 2024-02-01
IL277144B2 true IL277144B2 (en) 2024-06-01

Family

ID=67847428

Family Applications (1)

Application Number Title Priority Date Filing Date
IL277144A IL277144B2 (en) 2018-03-05 2019-03-05 Adenosine receptor antagonists and uses thereof

Country Status (12)

Country Link
US (3) US20210040097A1 (cg-RX-API-DMAC10.html)
EP (2) EP4364727A3 (cg-RX-API-DMAC10.html)
JP (3) JP7849948B2 (cg-RX-API-DMAC10.html)
KR (1) KR102754522B1 (cg-RX-API-DMAC10.html)
CN (1) CN112218867B (cg-RX-API-DMAC10.html)
AU (2) AU2019232736B2 (cg-RX-API-DMAC10.html)
BR (1) BR112020018158A2 (cg-RX-API-DMAC10.html)
ES (1) ES2975753T3 (cg-RX-API-DMAC10.html)
IL (1) IL277144B2 (cg-RX-API-DMAC10.html)
MX (1) MX2020009286A (cg-RX-API-DMAC10.html)
SG (1) SG11202008611UA (cg-RX-API-DMAC10.html)
WO (1) WO2019173380A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7849948B2 (ja) 2018-03-05 2026-04-22 テオン セラピューティクス,インク. アデノシン受容体アンタゴニストおよびその使用
BR112023002180A2 (pt) * 2020-08-07 2023-05-02 Teon Therapeutics Inc Terapia de combinação com antagonistas de receptor de adenosina
EP4211135A1 (en) * 2020-09-04 2023-07-19 Teon Therapeutics, Inc. Cocrystals of an adenosine a2b receptor antagonist
TW202313612A (zh) 2021-06-04 2023-04-01 美商天恩治療有限公司 腺苷ab受體拮抗劑的固體形式
TW202327612A (zh) * 2021-09-10 2023-07-16 美商天恩治療有限公司 使用腺苷受體拮抗劑之改良療法
EP4554943A1 (en) * 2022-07-14 2025-05-21 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof
WO2026035860A1 (en) 2024-08-07 2026-02-12 Teon Therapeutics, Inc. Formulations of adenosine receptor antagonist

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006138376A1 (en) * 2005-06-16 2006-12-28 Cv Therapeutics, Inc. Prodrugs of a2b adenosine receptor antagonists

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466811A (en) * 1994-07-18 1995-11-14 Merck & Co., Inc. Dioxolenylmethyl carbamates pro moieties for amine drugs
EP1075472A1 (en) * 1998-04-15 2001-02-14 Warner-Lambert Company Prodrugs of benzofuranylmethyl carbamate nk 1? antagonists
US7125993B2 (en) 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7304070B2 (en) 2001-11-09 2007-12-04 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US20080318983A1 (en) 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
AU2002359365B2 (en) * 2001-11-09 2008-07-10 Gilead Sciences, Inc. A2B adenosine receptor antagonists
US7317017B2 (en) 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
GEP20074230B (en) * 2002-03-20 2007-11-12 Bristol Myers Squibb Co Phosphate prodrugs of fluorooxindoles
WO2004106337A1 (en) * 2003-05-06 2004-12-09 Cv Therapeutics, Inc. Xanthine derivatives as a2b adenosine receptor antagonists
PL1789053T3 (pl) * 2004-09-01 2012-12-31 Gilead Sciences Inc Sposób gojenia się rany wykorzystujący antagonistów receptora adenozynowego A2B
EP2311462A1 (en) 2004-10-15 2011-04-20 Cv Therapeutics, Inc. Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
CA2646333C (en) 2006-03-17 2014-06-17 Cv Therapeutics, Inc. Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists
WO2008066627A2 (en) 2006-10-24 2008-06-05 Board Of Regents, The University Of Texas System Adenosine signaling in diagnosis, treatment and prevention of priapism and erectile dysfunction
WO2009088518A1 (en) 2008-01-11 2009-07-16 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for the treatment of cancer
JP5460690B2 (ja) * 2008-03-26 2014-04-02 アドヴィナス・セラピューティックス・リミテッド アデノシンレセプターアンタゴニストとしてのヘテロ環化合物
WO2009157938A1 (en) 2008-06-26 2009-12-30 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for treating cancer
NZ604423A (en) * 2010-06-24 2015-01-30 Alkermes Pharma Ireland Ltd Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
KR20130088834A (ko) 2010-06-30 2013-08-08 길리애드 사이언시즈, 인코포레이티드 폐 고혈압의 치료를 위한 a2b 아데노신 수용체 길항제의 용도
EP2616470B1 (en) * 2010-09-13 2016-10-12 Advinus Therapeutics Limited Purine compounds as prodrugs of a2b adenosine receptor antagonists, their process and medicinal applications
AR085942A1 (es) 2011-04-07 2013-11-06 Gilead Sciences Inc Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio
WO2012170209A2 (en) * 2011-05-23 2012-12-13 Nectid, Inc. Benzofuran-2 carboxamide compounds
US10117868B2 (en) 2011-10-25 2018-11-06 Case Western Reserve University Systems pharmacology for treating ocular disorders
US10702476B2 (en) 2017-08-14 2020-07-07 Phosphorex, Inc. Microparticle formulations of adenosine receptor antagonists for treating cancer
KR20200103018A (ko) 2017-12-19 2020-09-01 주식회사 지피씨알 Gpcr 헤테로머 억제제 및 이의 용도
JP7849948B2 (ja) 2018-03-05 2026-04-22 テオン セラピューティクス,インク. アデノシン受容体アンタゴニストおよびその使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006138376A1 (en) * 2005-06-16 2006-12-28 Cv Therapeutics, Inc. Prodrugs of a2b adenosine receptor antagonists

Also Published As

Publication number Publication date
US20210163483A1 (en) 2021-06-03
EP4364727A2 (en) 2024-05-08
IL277144B1 (en) 2024-02-01
JP2024032976A (ja) 2024-03-12
CA3093234A1 (en) 2019-09-12
KR20200132901A (ko) 2020-11-25
EP4364727A3 (en) 2024-05-15
US11124515B2 (en) 2021-09-21
AU2024204483B2 (en) 2026-04-02
ES2975753T3 (es) 2024-07-12
AU2019232736B2 (en) 2024-05-02
US20220056033A1 (en) 2022-02-24
SG11202008611UA (en) 2020-10-29
US20210040097A1 (en) 2021-02-11
EP3762386B1 (en) 2024-01-24
EP3762386A1 (en) 2021-01-13
AU2024204483A1 (en) 2024-07-18
CN112218867B (zh) 2023-11-21
JP2026074199A (ja) 2026-05-01
IL277144A (en) 2020-10-29
CN112218867A (zh) 2021-01-12
BR112020018158A2 (pt) 2021-02-02
AU2019232736A1 (en) 2020-10-08
JP2021517164A (ja) 2021-07-15
WO2019173380A1 (en) 2019-09-12
JP7849948B2 (ja) 2026-04-22
KR102754522B1 (ko) 2025-01-13
EP3762386A4 (en) 2021-11-24
MX2020009286A (es) 2020-12-11

Similar Documents

Publication Publication Date Title
IL277144B1 (en) Adenosine receptor antagonists and uses thereof
ES2734288T3 (es) Inhibidores de miristato de moléculas pequeñas de Bcr-abl y métodos de uso
ES2608329T3 (es) Imidazo[1,2-b][1,2,4]triazinas como inhibidores de c-Met
RU2010111551A (ru) Замещенные индольные производные и способы их применения
ES2830446T3 (es) Derivado de azetidina, método de preparación del mismo y uso del mismo
HRP20141169T1 (hr) Makrocikliäśki inhibitori serin proteaze hepatitisa c
HRP20150489T1 (hr) Imidazo[4,5-c]kinolini kao inhibitori dna-pk
AR076794A1 (es) Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
RU2010111550A (ru) 2,3-замещенные индольные производные для лечения вирусных инфекций
AR070540A1 (es) Derivados de 6-oxo-5, 6-dihidro-benzo[c][1, 8]naftiridina, un proceso para su preparacion, un kit que los incluye y su uso en la fabricacion de medicamentos para el tratamiento del cancer.
JP2007505933A5 (cg-RX-API-DMAC10.html)
IL276152B1 (en) Estrogen receptor modulating compounds
AR066904A1 (es) Pirrolopiridinas y pirazolopiridinas sustituidas como moduladores de las quinasas, una composicion farmaceutica que las incluye y su uso en el tratamiento del cancer
ME02875B (me) Inhibitori hcv polimeraze
JP2016513737A5 (cg-RX-API-DMAC10.html)
AR074165A1 (es) Antagonistas de heteroalquilo de receptores de prostaglandina d2 y composiciones farmaceuticas
RU2009127855A (ru) 4,5 циклоаннелированные производные индола для лечения или предотвращения вируса гепатита с (hcv) и родственных вирусных инфекций
US9181199B2 (en) Uracil derivatives and use thereof
IL295518A (en) Heterocyclic compounds used as pdk1 inhibitors
RU2018127728A (ru) Слитые трициклические гетероциклические соединения в качестве ингибиторов интегразы вич
EP3868764A1 (en) Sting-agonist compound
ATE427949T1 (de) 4-a4-(5-oxo-2,3,5,11a-tetrahydro-5h-pyrrolo a2, 1-cua1,4ubenzodiazepin-8-yloxy)-butyrylaminou-1 - pyrrol-2-carbonsaurealkylesterderivate und verwandte verbindung zur behandlung einer proliferativen erkrankung
RU2009105826A (ru) 2,4-ди(ариламино)питимидин-5-карбоксамидные соединения в качестве ингибиторов jak-киназ
JP2016522232A (ja) ヘテロアリール置換されたピラゾール類
JP2018522852A5 (cg-RX-API-DMAC10.html)